Anika Therapeutics
ANIK
133 hedge funds and large institutions have $179M invested in Anika Therapeutics in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 12 closing their positions.
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
23% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 40
2% more funds holding
Funds holding: 130 → 133 (+3)
0% less capital invested
Capital invested by funds: $179M → $179M (-$6.35K)
0.26% less ownership
Funds ownership: 92.22% → 91.97% (-0.26%)
67% less call options, than puts
Call options by funds: $1K | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$4.26M |
| 2 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$1.68M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.12M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$531K |
| 5 |
Jane Street
New York
|
+$457K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.82M |
| 2 |
BlackRock
New York
|
-$2.15M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$1.36M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$755K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$713K |
ANIK Hedge Fund Activity: Q2 2026 in Review
133 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2026, worth a combined $179M — down 0% from $179M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ANIK positions and 12 closed out — a net gain of 7 holders — while 49 added to existing stakes and 40 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $4.26M. The largest seller was Morgan Stanley, cutting an estimated $3.82M.
- 133 institutional investors held Anika Therapeutics (ANIK) as of Q2 2026, up from 130 in Q1 2026.
- Funds reported $179M of Anika Therapeutics stock for Q2 2026, down 0% quarter-over-quarter.
- 19 funds opened new Anika Therapeutics positions in Q2 2026 and 12 closed out, a net change of +7 holders.
- The largest Anika Therapeutics buyer in Q2 2026 was AQR Capital Management, an estimated $4.26M added.
- The largest Anika Therapeutics seller in Q2 2026 was Morgan Stanley, an estimated $3.82M sold.
Based on aggregated 13F filings for Q2 2026.